CAMBRIDGE, Mass., May 18 /PRNewswire/ -- Gene Network Sciences (GNS) today announced that Peter Rock is joining the company as chief financial officer. In this role, he will oversee the finance, reporting and operations functions at GNS. Rock will be working at the company’s Cambridge, Mass., office.
To his new role, Rock brings more than 15 years of experience, a majority of which has been with life sciences companies. He currently serves as chairman of the Business Solutions Advisory Board for BIO and previously held the post of co-chairman of the Massachusetts Biotechnology Council’s Finance Committee. Over the past four years, Rock served as the principal of Rock Consulting and provided financial guidance to a number of start-up biotech and technology companies.
Rock previously spent five years as vice president and corporate controller of Dyax Corp., a biotech company with revenues of $33 million a year. While at Dyax, he helped to streamline monthly closing cycles, secure $32 million in venture financing, and raise $69 million through a successful IPO. Rock was involved in the financial aspects of licensing and collaborative deal structures, the acquisition of an overseas technology company, and oversaw a $10 million facility build-out.
Prior to Dyax, Rock held various financial management positions at Avery-Dennison, AEG Schneider Automation, Inc. and United Technologies Corporation.
“Peter has a strong track record of financial and business leadership,” said Colin Hill, CEO of Gene Network Sciences. “His broad industry perspective and directly relevant experience will be a great asset for GNS as we continue growing.”
About Gene Network Sciences
Founded in 2000, Gene Network Sciences (www.gnsbiotech.com) is a privately held biosimulation company with offices in Ithaca, New York, and Cambridge, Massachusetts. GNS creates cell and organ-level computer models able to simulate the clinical performance of drugs and drug candidates. By predicting how and why specific compounds impact human biology and specific sub- populations, GNS technology increases clinical trial success rates and helps bring better drugs to market faster.
Gene Network Sciences
CONTACT: Debbie Pfeifer of Gene Network Sciences, +1-206-282-5098, ordebbie@gnsbiotech.com
Web site: http://gnsbiotech.com//
